Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents

Author(s): Burak Pamukcu, Kurt Huber and Gregory Y.H. Lip

Volume 18, Issue 6, 2012

Page: [850 - 860] Pages: 11

DOI: 10.2174/138161212799277716

Price: $65

Abstract

Aspirin has long been the mainstay of primary and secondary prevention against myocardial infarction and ischemic cerebrovascular events. However, the incremental value of aspirin for primary prevention has recently been subject to debate given data from recent large clinical trials, as the net clinical benefit is small. In secondary prevention, aspirin is still strongly recommended.

Efforts in obtaining more efficient antiplatelet agents and to reduce cardiovascular morbidity and mortality have led to the development of new adenosine diphosphate (ADP) receptor antagonists, which are superior to clopidogrel. New generation antiplatelet drugs i.e. prasugrel and ticagrelor aim to reduce atherothrombotic events, mortality and stent thrombosis, as well as overcome low- or non-response to clopidogrel. Further agents with antiplatelet properties are being investigated at present.

This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases.

Keywords: Atherothrombosis, cardiovascular disease, primary prevention, secondary prevention, novel antithrombotics, acetyl salicylic acid, adenosine diphosphate (ADP), infarction, ischemic cerebrovascular, clopidogrel

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy